ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Biolipid Film-Fused Electrochemiluminescence for Multipurpose In Situ Bioassays.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Electrochemiluminescence (ECL) is intrinsically a surface-state-sensitive strategy, yet its seamless synergy with soft biomembranes remains sparsely explored. Herein, a biolipid-bound, membrane-interactive scaffold is built upon an ECL-emissive artificial nanochannel and smoothly blended into supported phospholipid bilayers containing cholesterol and diversified natural or synthetic lipids. Such bilayer-bridged assemblies preserve efficient emission while permitting dynamic membrane remodeling. The resulting biointerface enables label-free profiling of cytomembrane-active species, including divalent cations, amphiphilic pharmaceuticals, and pore-forming peptides, through real-time isotherm and kinetic analysis. By further integrating phospholipid-pendant recognition motifs, femtomolar detection of Alzheimer's disease biomarkers (β-amyloid polypeptide and tau protein) is achieved. Moreover, vesicle-mediated membrane merging embeds ECL emitters into living-cell plasmalemma, affording surface-confined single-cell visualization using endogenous oxygen as the coreactant. Collectively, this biointerface-compatible ECL paradigm enables multiplexed monitoring of molecular, membranous, and cellular processes via membrane-structural modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.